Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension
Information source: Takeda
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Candesartan cilexetil and hydrochlorothiazide (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Takeda Official(s) and/or principal investigator(s): Medical Director, Study Director, Affiliation: Takeda Pharma GmbH (Germany)
Summary
The purpose of this study is to see if Candesartan, once daily (QD), added with
Hydrochlorothiazide may be helpful in treating people with newly diagnosed severe essential
hypertension.
Clinical Details
Official title: Clinical Study to Evaluate the Efficacy and Safety of the Combination Therapy Candesartan Cilexetil 32 mg Plus Hydrochlorothiazide 25 mg in Patients With Severe Hypertension
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Change from Baseline in Systolic Blood Pressure at Week 9.Change from Baseline in Diastolic Blood Pressure at Week 9.
Secondary outcome: Percentage of subjects showing a decrease in SBP to less than 140 mmHg and/or a decrease of SBP by at least 20 mmHg AND a decrease in DBP to less than 90 mmHg and/or a decrease of DBP by at least 10 mmHg.Percentage of subjects showing a decrease in SBP to less than 130 mmHg and/or a decrease of SBP by at least 20 mmHg AND a decrease in DBP to less than 80 mmHg and/or a decrease of DBP by at least 10 mmHg. Change from Baseline in Pulse Rate at Week 9. Change from Baseline in Systolic Blood Pressure at Final Visit. Change in Baseline in Diastolic Blood Pressure at Final Visit. Change from Baseline in Pulse Rate at Final Visit.
Detailed description:
Medical data show a link between blood pressure and the risk of heart disease
(cardiovascular disease) such as stroke and heart attack. Clinical trials have shown that
lowering blood pressure in patients with high blood pressure (hypertension) reduces the
number of cardiovascular events.
Many people still have untreated hypertension. There are many reasons why target blood
pressure is not reached. One is that most patients need more than one antihypertensive drug
in order to lower high blood pressure. Other reasons include poor patient compliance with
taking their drugs.
Combining drugs that lower high blood pressure and have similar ways of working in the body
may help high blood pressure and lower the risk for medication-related side effects. One of
several drug combinations recommended for the treatment of high blood pressure is an
angiotensin receptor blocker and a thiazide diuretic. Guidelines also note that combination
tablets may improve patient compliance with taking their drugs.
Candesartan is an angiotensin type-1 receptor blocker. Hydrochlorothiazide is a diuretic
with blood pressure-lowering effect. This study will combine both of these drugs in one pill
and see how it works in people taking part in this study.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Confirmed diagnosis of essential hypertension.
- Has Systolic Blood Pressure between 150 mmHg and 200 mmHg AND Diastolic Blood
Pressure between 110 mmHg and 120 mmHg.
- Has not received any antihypertensive treatment so far.
- Has a negative pregnancy test at baseline in females of childbearing potential. Male
and female participants with reproductive potential must use an approved
contraceptive method during study treatment evaluation
Exclusion Criteria:
- Has a known or suspected secondary hypertension or primary hyperaldosteronism.
- Has impaired renal function.
- Has severe hepatic impairment.
- Has bilateral renal artery stenosis, solitary kidney or post-renal transplant status.
- Has a history of myocardial infarction, coronary artery bypass graft, percutaneous
coronary intervention or cerebral accident (stroke or transient ischaemic attack)
within the last 6 months.
- Has a diagnosis or suspicion of the following conditions: hypertrophic obstructive
cardiomyopathy, angina pectoris, chronic heart failure, peripheral arterial occlusive
disease, hypertensive retinopathy.
- Has hemodynamically relevant stenosis of the aortic or mitral valve.
- Has clinically relevant and refractory hypokalaemia or hyperkalaemia.
- Has uncorrected volume or sodium depletion.
- Has gout or relevant hyperuricaemia.
- Has a known intolerance/hypersensitivity to Candesartan cilexetil or
Hydrochlorothiazide.
- Has a known galactose intolerance, lactase deficiency or glucose-galactose
malabsorption.
- Is taking psychotropic medication or is addicted to alcohol or drugs.
- Has participated in another trial of an investigational drug or a medical device
within the last 30 days or is currently participating in another trial of an
investigational drug or a medical device.
Locations and Contacts
Berlin, Germany
Blankenhain, Germany
Dortmund, Germany
Hamburg, Germany
Köthen, Germany
Löhne, Germany
Nürnberg, Germany
Remscheid, Germany
Rodgau, Germany
Stockach, Germany
Wardenburg, Germany
Weinheim, Germany
Ivano-Frankivsk, Ukraine
Kharkiv, Ukraine
Kiev, Ukraine
Lviv, Ukraine
Additional Information
Starting date: October 2009
Last updated: July 12, 2010
|